Cargando…
Association of Radiotherapy Duration With Clinical Outcomes in Patients With Esophageal Cancer Treated in NRG Oncology Trials: A Secondary Analysis of NRG Oncology Randomized Clinical Trials
IMPORTANCE: For many types of epithelial malignant neoplasms that are treated with definitive radiotherapy (RT), treatment prolongation and interruptions have an adverse effect on outcomes. OBJECTIVE: To analyze the association between RT duration and outcomes in patients with esophageal cancer who...
Autores principales: | Hallemeier, Christopher L., Moughan, Jennifer, Haddock, Michael G., Herskovic, Arnold M., Minsky, Bruce D., Suntharalingam, Mohan, Zeitzer, Kenneth L., Garg, Madhur K., Greenwald, Bruce D., Komaki, Ritsuko U., Puckett, Lindsay L., Kim, Hyun, Lloyd, Shane, Bush, David A., Kim, Harold E., Lad, Thomas E., Meyer, Joshua E., Okawara, Gordon S., Raben, Adam, Schefter, Tracey E., Barker, Jerry L., Falkson, Carla I., Videtic, Gregory M. M., Jacob, Rojymon, Winter, Kathryn A., Crane, Christopher H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10122174/ https://www.ncbi.nlm.nih.gov/pubmed/37083668 http://dx.doi.org/10.1001/jamanetworkopen.2023.8504 |
Ejemplares similares
-
Serum testosterone changes in patients treated with radiation therapy alone for prostate cancer on NRG oncology RTOG 9408
por: Nichols, R. Charles, et al.
Publicado: (2017) -
NRG Oncology Survey on Practice and Technology Use in SRT and SBRT Delivery
por: Chetvertkov, Mikhail, et al.
Publicado: (2020) -
Risk factors for late bowel and bladder toxicities in NRG Oncology prostate cancer trials of high-risk patients: A meta-analysis of physician-rated toxicities
por: Xiao, Canhua, et al.
Publicado: (2018) -
Impact of tumour histology on survival in advanced cervical carcinoma: an NRG Oncology/Gynaecologic Oncology Group Study
por: Seamon, Leigh G, et al.
Publicado: (2018) -
Reduced-Dose Radiation Therapy for HPV-Associated Oropharyngeal Carcinoma (NRG Oncology HN002)
por: Yom, Sue S., et al.
Publicado: (2021)